Use of programmed cell death protein 1 (PD-1) inhibitor therapy in HIV-infected patients with advanced cancer: a single-center study from China.

Wu, Luling; Su, Jie; Yang, Junyang; Gu, Ling; Zhang, Renfang; Liu, Li; Lu, Hongzhou; Chen, Jun.

Afiliação

Wu L; Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Su J; Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Yang J; State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Rui-Jin Hospital, Shanghai Jiao Tong University School of Medicine and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
Gu L; Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Zhang R; Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Liu L; Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Lu H; Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Chen J; Department of Infectious Diseases and Nursing Research Institution, National Clinical Research Center for Infectious Diseases, The Third People's Hospital of Shenzhen, Shenzhen, China. luhongzhou@fudan.edu.cn.

Infect Agent Cancer ; 18(1): 35, 2023 May 30.

Article em En | MEDLINE | ID: mdl-37254144